By: Jan Chait
Fourteen entities have joined forces to form Type 1 Diabetes TrialNet, a collaborative effort to test new approaches to understanding, preventing and treating type 1 diabetes. Recruitment for the first trials is expected to begin in early 2003.
Prevention trials will attempt to stop or delay the destruction of insulin-producing beta cells in people at risk for type 1 diabetes. Treatment trials will try to preserve remaining beta cells in those with new-onset type 1 diabetes.
“TrialNet will expedite the application of discoveries in basic research to therapies that benefit people with type 1 diabetes and those at risk,” says Jay Skyler, MD, of the University of Miami.
Skyler, who is the study chair for TrialNet, oversaw the Diabetes Prevention Trial Type 1 (DPT-1). DPT-1 had two components: a low-dose insulin injection trial that ended in 2001 after discovering that the injections failed to prevent type 1 diabetes; and an oral insulin trial, which will become part of the new TrialNet.
“Mounting individual trials for prevention of type 1 diabetes is a challenging, costly endeavor,” says Allen Spiegel, MD, director of the National Institute of Diabetes and Digestive and Kidney Diseases, which leads the initiative. “This network provides a stable, efficient, cost-effective system for identifying people at risk for type 1 diabetes and testing the ability of promising new agents to prevent the disease.”
For more information about TrialNet, call (800) 425-8361.